31 Dec 2013 12:34
31 December 2013
The following amendment has been made to the 'Total Voting Rights' announcement released on 31 December 2013 at 08:00 under RNS No 3221W.
The number of total Common Shares in issue and held in treasury were incorrect and should have read 2,167,837 Common Shares in issue and no Common Shares held in treasury.
All other details remain unchanged.
The full amended text is shown below.
31 December 2013
Akers Biosciences, Inc.
("ABI" or the "Company")
Total Voting Rights
NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION OR DISSEMINATION IN OR INTO OR FROM THE UNITED STATES, CANADA, AUSTRALIA, JAPAN OR SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION
Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, today announces that the Company's total issued share capital at the date of this announcement comprises of 2,167,837 common shares of no par value ("Common Shares"). The Company holds no Common Shares in treasury, therefore the total number of Common Shares with voting rights in the Company is 2,167,837.
The above figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.
About Akers Biosciences, Inc.
Akers Biosciences develops, manufactures, and supplies rapid, point‐of‐care screening and testing products designed to bring health status information, both rapidly and directly, to the consumer or healthcare provider. The Company has advanced the science of diagnostics while responding to major shifts in healthcare through the development of several proprietary platform technologies. The Company's state‐of‐the‐art rapid diagnostic assays can be performed virtually anywhere, in minutes, since time is always of essence. ABI is aligned with high volume medical product distributors to help facilitate the Company's growth into a major, worldwide competitor in the field of rapid diagnostics. Additional information on the Company and its products can be found at www.akersbiosciences.com
Enquiries:
Thomas A. Nicolette
President and CEO
Tel. +1 856 848 8698
Antony Legge or James Thomas
Daniel Stewart & Company plc (Nomad and Broker)
Tel. +44 (0)20 7776 6550
Ben Simons
Vigo Communications
Tel. +44 (0) 20 7016 9574